Diabetic Nephropathy Larry Lehrner, Ph.D.,M.D.
|
|
- Roberta Blair
- 6 years ago
- Views:
Transcription
1 Diabetic Nephropathy Larry Lehrner, Ph.D.,M.D. Commercial Support Acknowledgement: There is no outside support for this activity Financial Disclosure: stocks > 50,000 Bayer, J&J, Norvartis,Novo Nordisk, Pfizer, Sanofi
2 Diabetic Nephropathy Presentation Outline Definition of DN Classification of CKD Mechanisms for the Development of DN Goals of Treatment and Literature Confusion Primary Care Treatment of DN Improved Clinical Outcomes Future References/Major Studies Summary- for your reading pleasure at home
3 Diabetic Nephropathy Presentation Outline Definition of DN Classification of CKD Mechanisms for the Development of DN Goals of Treatment and Literature Confusion Primary Care Treatment of DN Improved Clinical Outcomes Future References/Major Studies Summary
4 Definition of Diabetic Nephropathy Persistent albuminuria (>300 mg/24 hr or 200 µg/min) is the hallmark of diabetic nephropathy that can be diagnosed clinically if the following additional criteria are fulfilled presence of diabetic retinopathy and absence of clinical or laboratory evidence of other kidney or renal tract disease. This clinical definition of diabetic nephropathy is valid in types 1 and 2 diabetes (pg 1283) only 50% to 60% of proteinuric type 2 diabetic patients have retinopathy. (pg 1300) Brenner and Rector's The Kidney, 39, e14 Diabetic kidney disease is usually a clinical diagnosis made based on the presence of albuminuria and/or reduced egfr in the absence of signs or symptoms of other primary causes of kidney damage. The typical presentation of diabetic kidney disease is considered to include a long-standing duration of diabetes, retinopathy, albuminuria without hematuria, and gradually progressive kidney disease. However, signs of CKD may be present at diagnosis or without retinopathy in type 2 diabetes, and reduced egfr without albuminuria has been frequently reported in type 1 and type 2 diabetes and is becoming more common over time as the prevalence of diabetes increases in the U.S. American Diabetes Association- Diabetes Care Volume 40, Supplement 1, January 2017
5 Definition of Diabetic Nephropathy prevalence of albuminuria in patients with T2DM decreased from about 21% in to 16% in , despite a rise in the prevalence of reduced egfr CJASN 12: ,2017
6 DM Nephropathy Not Just a Glomerular Disease Diabetic Classic Kimmelstiel-Wilson nodule Thickened renal arterial wall
7 Pathologic Classification of DM Nephropathy
8 Pathologic Classification of DM Nephropathy IFTA = Interstitial fibrosis and tubular atrophy
9 Diabetic Nephropathy Presentation Outline Definition of DN Classification of CKD Mechanisms for the Development of DN Goals of Treatment and Literature Confusion Primary Care Treatment of DN Improved Clinical Outcomes Future References/Major Studies Summary
10 Estimating GFR- Cr, Age, Race, Sex The MDRD GFR is an estimate of the glomerular filtration rate (GFR) using serum creatinine and demographic factors. It has not been studied extensively in populations that are not white or black. It relies on a stable creatinine and may be less accurate for GFR values above 60. simplified MDRD equation by Levey, et. al. egfr = 186*(0.742 if female)*(1.212 if Black)*creatinine *age The CKD-EPI GFR is an estimate of the glomerular filtration rate (GFR) using serum creatinine and demographic factors. It is a relatively new equation proposed to be superior to the MDRD GFR equation. The CKD-EPI equation by Levey, et. al.: egfr = 141 x min(scr/k, 1) a x max(scr/k, 1) x Age x [if female] x [if black] Scr is serum creatinine, k is 0.7 for females and 0.9 for males, a is for females and for males, min indicates the minimum of Scr/k or 1, and max indicates the maximum of Scr/k or 1 Levey AS, Greene T, Kusek J, Beck GJ, Group MS: A simplified equation to predict glomerular filtration rate from serum creatinine [Abstract]. J Am Soc Nephrol 11: A0828, 2000 Levey et al.a new equation to estimate glomerular filtration rate. Ann Intern Med 2009;150:
11 CKD Stages < 30 mg/day mg/day > 300 mg/day < 20 ug/min ug/min > 200 ug/min UAE ACR Albumin/min
12 Diabetic Nephropathy Presentation Outline Definition of DN Classification of CKD Mechanisms for the Development of DN Goals of Treatment and Literature Confusion Primary Care Treatment of DN Improved Clinical Outcomes Future References/Major Studies Summary
13 Pathogenic processes in DN and potential targeting strategies under clinical investigation. Bioorganic & Medicinal Chemistry Letters Volume 26, Issue 18, 15 September 2016, Pages
14 Potential Mechanisms for the Development of DM Nephropathy A Target Rich Environment Journal of Advanced Research Volume 8, Issue 4, July 2017, Pages
15 Diabetic Nephropathy Presentation Outline Definition of DN Classification of CKD Mechanisms for the Development of DN Goals of Treatment and Literature Confusion Primary Care Treatment of DN Improved Clinical Outcomes Future References/Major Studies Summary
16 What Do Most Studies Evaluate? A Specific Organ System such as Cardiac or Renal For Renal Studies What Are the Usually Measured End Points? Proteinuria Doubling of Serum Creatinine Development of ESRD What do we Really Want to Accomplish with Treatment of Diabetes Improve morbidity Improve mortality
17 Life Cycle of Diabetic Nephropathy in T1DM and 3 Points of Intervention A2- microalbuminuria to A3- Macroalbuminuria (diabetic nephropathy) A3- macroalbuminuria (DN) to ESRD Type 1 DM Changing nomenclature A1-normoalbuminuria to A2- microalbuminuria microalbuminuria = moderately increased albuminuria (A2) macroalbuminuria = severely increased albuminuria (A3)
18 Potential Issues with Studies T1DM vs. T2DM What phase is being studied- primary prevention, secondary prevention, tertiary prevention Only about 30% of diabetic patients develop DN- thus in primary prevention studies about 70% of enrolled patients will NOT develop the disease no matter the treatment. Need for better biomarkers of which patients are at risk for DN Sex differences- young males worse outcomes. Estrogen protective? Is the study drug s mechanism of action independent of glycemic and/or BP control
19 Is Albuminuria an Appropriate Surrogate Marker of Renoprotection? Albuminuria Is an Appropriate Therapeutic Target in Patients with CKD: The Pro View Clin J Am Soc Nephrol Jun 5; 10(6): reduction in albuminuria observed during the first months of treatment with these drugs correlates with the degree of long-term renal protection: the larger the initial reduction in albuminuria, the lower the risk of ESRD during treatment. In addition, in treated patients, residual albuminuria is again the strongest risk marker for renal disease progression. These observations combined provide a strong argument that albuminuria is an appropriate therapeutic target in patients with CKD Albuminuria is Not an Appropriate Therapeutic Target in Patients with CKD: The Con View Clin J Am Soc Nephrol Jun 5; 10(6): combining renin-angiotensin system therapies decreases albuminuria without significant clinical benefit but with increased risk of adverse events albuminuria has not jumped the hurdle needed to be accepted as a surrogate end point or target for treatment. Primum non nocere, first do no harm.
20 Diabetic Nephropathy Presentation Outline Definition of DN Classification of CKD Mechanisms for the Development of DN Goals of Treatment and Literature Confusion Primary Care Treatment of DN Improved Clinical Outcomes Future References/Major Studies Summary
21 Primary Care Treatment Make the Dx of DN When to Test For Albuminuria T1DM- 5 years after Dx of DM (sooner if poor control and/or hypertensive) T2DM- upon Dx of DM Disease-a-Month Volume 61, Issue 9, September 2015, Pages
22 Primary Care Make the Dx of DN If you do not look for a disease you will never find it vol 1 Figure 2.3 Trends in percent of patients with testing of urine albumin (a) in Medicare 5% sample (aged 65+ years) patients without a diagnosis of CKD, by year from 2005 to 2015 (a) Medicare 5% Data Source: Special analyses, Medicare 5% sample aged 65 and older with Part A & B coverage in the prior year and Optum Clinformatics patients aged years. Tests tracked during each year. Abbreviations: CKD, chronic kidney disease; DM, diabetes mellitus; HTN, hypertension Annual Data Report Volume 1 CKD, Chapter 2 22
23 Primary Care Treatment Make the Dx of DN The lack of albuminuria does not exclude DN When to Test For egfr egfr T2DM T1DM Ø 90 yearly at Dx then yearly starting at year 5 Ø yearly yearly Ø q3 months q3 months Ø q6-8 weeks q6-8 weeks Ø <15 q4 weeks q4 weeks My opinion
24 Primary Care Make the Dx of DN If you do not look for a disease you will never find it Figure 2.3 Trends in proportion of patients (b) serum creatinine testing, by year, among Medicare patients aged 65+ WITHOUT a diagnosis of CKD, (b) Serum Creatinine Data Source: Special analyses, Medicare 5 percent sample, aged 65 and older with Part A & B coverage in the prior year. Tests tracked during each year. Abbreviations: CKD, chronic kidney disease; DM, diabetes mellitus; HTN, hypertension. USRDS Vol 1, CKD, Ch
25 Primary Care Treatment- General Measures Ø Weight Loss Ø Smoking Cessation Ø Modest Protein Restriction 0.8 mg/kg Ø Lipid Management Ø Uric Acid Management Ø Acidosis Management Journal of Advanced Research Volume 8, July 2017 pg J Diabetes Res. 2015; 2015: doi: /2015/ Canadian Journal of Diabetes Volume 39, Issue 3, June 2015, Pages BMC Nephrol. 2015; 16: 58. doi: /s z
26 Primary Care Treatment Glycemic Control and BP Control
27 Primary Care Treatment- BP Hypertension Common DM comorbidity Major risk factor for ASCVD & microvascular complications Antihypertensive therapy reduces ASCVD events, heart failure, and microvascular complications. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes Diabetes Care 2018; 41 (Suppl. 1): S86-S104
28
29 Pharmacologic Interventions Treatment for hypertension should include drug classes demonstrated to reduce CV events in patients with diabetes: A ACE Inhibitors Angiotensin receptor blockers (ARBs) Thiazide-like diuretics Dihydropyridine calcium channel blockers e.g. Amlopidine Primary Care Treatment- BP Hypertension/BP Control: Recommendations (5) Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes Diabetes Care 2018; 41 (Suppl. 1): S86-S104
30 Hypertension/BP Control: Recommendations (6) Pharmacologic Interventions Multiple-drug therapy is generally required to achieve BP targets. However, combinations of ACE inhibitors and ARBs and combinations of ACE inhibitors or ARBs with direct renin inhibitors should not be used. A Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes Diabetes Care 2018; 41 (Suppl. 1): S86-S104
31 Hypertension/BP Control: Recommendations (7) Pharmacologic Interventions An ACE inhibitor or ARB, at the maximumly tolerated dose indicated for BP treatment, is the recommended first-line treatment for hypertension in patients with diabetes and urinary albumin-to-creatinine ratio 300 mg/g creatinine A or mg/g creatinine B. If one class is not tolerated, the other should be substituted. B For patients treated with an ACE inhibitor, ARB, or diuretic, serum creatinine/estimated glomerular filtrated rate and serum potassium levels should be monitored at least annually. B Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes Diabetes Care 2018; 41 (Suppl. 1): S86-S104
32 Classic Study Showing ACEI is Renoprotecitve NEJM 1993;329:
33 ACEI For Renoprotection- CKD Stage is Important NEJM 1993;329:
34 Diabetic Kidney Disease (DKD): Recommendations (5) Treatment An ACE inhibitor or an ARB is not recommended for the primary prevention of DKD in patients with diabetes who have normal blood pressure, normal UACR (<30 mg/g creatinine), and normal egfr. B When egfr rate is <60 ml/min/1.73m 2, evaluate and manage potential complications of DKD. E Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes Diabetes Care 2018; 41 (Suppl. 1): S105-S118
35 What is the Optimal BP for Patients with Diabetic Nephropathy?
36 Most people with diabetes and hypertension should be treated to a systolic BP goal of <140 mmhg and a diastolic BP goal of <90 mmhg.
37 SJ Taler. N Engl J Med 2018;378: Classification of Blood Pressure in Adults.*
38 Synopsis of the 2017 ACC/AHA Hypertension Guideline Table 4. Recommendations for Nonpharmacologic and Pharmacologic Treatment and BP Goals* BP threshold and goal for adults with DM In adults with DM and hypertension, initiate antihypertensive drug therapy at SBP 130 mm Hg (class I recommendation; level of evidence: B-R) or DBP 80 mm Hg (class I recommendation; level of evidence: C-EO) and treat to goal of <130/80 mm Hg (class I recommendation; level of evidence: B-R) AnnInternMed. 2018;168: doi: /m
39 Primary Care Treatment- Glucose Diabetic Kidney Disease (DKD): Recommendations (2) Treatment Optimize glucose control to reduce the risk or slow progression of DKD. A Optimize blood pressure control to reduce the risk or slow progression of DKD. A For people with nondialysis-dependent DKD, dietary protein intake should be ~0.8 g/kg body weight per day (the recommended daily allowance). For patients on dialysis, higher levels of dietary protein intake should be considered. B Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes Diabetes Care 2018; 41 (Suppl. 1): S105-S118
40 Intensive Glucose Control in T1DM NO Retinopathy A2 Retinopathy A2 A3 A3 N Engl J Med 1993; 329: September 30, 1993DOI: /NEJM
41 Summary of Intense Glycemic Control in T2DM Thus, as a whole, the intensity of glycemic control should probably be tempered in patients with T2DM who also have multiple comorbid conditions, with the goal of moderate glycemic control (HbA1C 7 8 %), since the benefits, if any, are hard to achieve, come with risk, and are at best small in magnitude. Intensive glycemic control with HbA1C <7 % should be attempted with extreme caution and only in younger, newly diagnosed patients without comorbidities. Update on Glycemic Control for the Treatment of Diabetic Kidney Disease Curr Diab Rep (2015) 15: 42 DOI /s
42 Intensive Glucose Control in T2DM
43 Diabetic Nephropathy Presentation Outline Definition of DN Classification of CKD Mechanisms for the Development of DN Goals of Treatment and Literature Confusion Primary Care Treatment of DN Improved Clinical Outcomes Future References/Major Studies Summary
44 CKD Patients Are More Likely to Die Than Progress to ESRD Percentage Who Remained Event-Free vs Death vs Developed ESRD During 5-Year Follow-up % of Patients 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% 15% 16% 10% 7% 28% 64% 63% 75% 20% 1% 46% 20% 24% 10% Stage 1 Stage 2 Stage 3 Stage 4 Disenrolled Event free RRT Died Keith et al. J Am Soc Nephrol. 13:620A, 2002.
45 CKD Patients Are More Likely to Die Than Progress to ESRD Percentage Who Remained Event-Free vs Death vs. Developed ESRD During 2-Year Follow-up. Patients had their first Nephrology consult at an outpatient clinic 100% 80% % of Patients 60% 40% 20% 0% 90% 84% 1% 8% 12% No DM, No CKD 4% 68% 11% 61% 18% 20% 22% DM, No CKD No DM, CKD DM, CKD Status at Entry Period Event Free ESRD Death Medicare 5% sample , Two year follow-up, adjusted for age, gender, and race Analysis performed by Minneapolis Medical Research Foundation
46 vol 2 Figure 1.7 Trends in (a) ESRD incident cases, in thousands, and (b) adjusted* ESRD incidence rate, per million/year, by primary cause of ESRD, in the U.S. population, (a) Incident Cases IC (b) Incidence Rates IR Data Source: Reference tables A.1, A.2(2). *Adjusted for age, sex, and race. The standard population was the U.S. population in Abbreviation: ESRD, end-stage renal disease. Simple Mathematical Example- Incident Cases (IC) vs Incident Rate (IR) Population 1,000,000 5,000,000 New Patients (IC) 1,000 3,750 Incident Rate/Million (IR) 1, USRDS 2014 Vol 2, ESRD, Ch 1 46
47 Diabetic Nephropathy Presentation Outline Definition of DN Classification of CKD Mechanisms for the Development of DN Goals of Treatment and Literature Confusion Primary Care Treatment of DN Improved Clinical Outcomes Future References/Major Studies Summary
48 Are SGLT2 Inhibitors Renal Protective Canagliflozin Placebo Total
49 Remember Is the Patient better off Not are one or two organ systems better off CONCLUSIONS In two trials involving patients with type 2 diabetes and an elevated risk of cardiovascular disease, patients treated with canagliflozin had a lower risk of cardiovascular events than those who received placebo but a greater risk of amputation, primarily at the level of the toe or metatarsal.
50 Proposed Mechanism Of Action Hyperglycemia & SGLT2 Inhibitors In Diabetics Tubuloglomerular feedback:impact of low salt intake and SGLT2 inhibitors. UF = glomerular ultrafiltrate; SGLT = sodium glucose transporter; PCT = proximal convoluted tubules; DCT = distal convoluted tubule; MD = macula densa; AMP = adenosine monophosphate; VD = vasodilation; AA = afferent arteriole Journal of Advanced Research Volume 8, Issue 4, July 2017, Pages
51 Are GLP-1 Agonists Renoprotective?
52 Proposed Mechanism Of Action DPP-4 GLP insulin secretion inflammation Angiotensin II DPP-4 mediated renal fibrosis. DPP4 = dipeptyl peptidase-4; TGFβ = transforming growth factorβ; EndMT = endothelial-mesenchymal transition Journal of Advanced Research Volume 8, Issue 4, July 2017, Pages
53 Incretin Dependent Incretin INDEPENDENT
54 Diabetic Nephropathy Presentation Outline Definition of DN Classification of CKD Mechanisms for the Development of DN Goals of Treatment and Literature Confusion Primary Care Treatment of DN Improved Clinical Outcomes Future References/Major Studies Summary- for your reading pleasure at home
55 Diabetic Nephropathy Larry Lehrner, Ph.D.,M.D. Thank You Commercial Support Acknowledgement: There is no outside support for this activity Financial Disclosure: stocks > 50,000 Bayer, J&J, Norvartis,Novo Nordisk, Pfizer, Sanofi
56 Review of Potential New Treatments for DN Selected References Therapies on the Horizon for Diabetic Kidney Disease Curr Diab Rep (2015) 15: 111 DOI /s Diabetic nephropathy: What does the future hold? Int Urol Nephrol (2016) 48: DOI /s y Mechanistic insight of diabetic nephropathy and its pharmacotherapeutic targets: An update European Journal of Pharmacology Volume 791, 15 November 2016, Pages 8-24 Management of diabetic nephropathy: Recent progress and future perspective Diabetes & Metabolic Syndrome: Clinical Research & Reviews 9 (2015) Diabetic nephropathy: landmark clinical trials and tribulations Nephrol Dial Transplant (2016) 31: doi: /ndt/gfu411
57 Approved Treatments for DM Nephropathy Journal of Advanced Research Volume 8, Issue 4, July 2017, Pages
58
59
60 Major DN Studies Nephrol Dial Transplant (2016) 31: doi: /ndt/gfu411
61 Major DN Studies Nephrol Dial Transplant (2016) 31: doi: /ndt/gfu411
62 Major DN Studies Nephrol Dial Transplant (2016) 31: doi: /ndt/gfu411
63 Nephrol Dial Transplant (2016) 31: doi: /ndt/gfu411 Major DN Studies
Diabetic Nephropathy
Diabetic Nephropathy Larry Lehrner, Ph.D.,M.D. llehrner@ksosn.com Commercial Support Acknowledgement: There is no outside support for this activity Financial Disclosure: stocks > 50,000 Bayer, J&J, Norvartis,Novo
More informationDiabetes and Hypertension
Diabetes and Hypertension M.Nakhjvani,M.D Tehran University of Medical Sciences 20-8-96 Hypertension Common DM comorbidity Prevalence depends on diabetes type, age, BMI, ethnicity Major risk factor for
More informationSGLT2 inhibition in diabetes: extending from glycaemic control to renal and cardiovascular protection
SGLT2 inhibition in diabetes: extending from glycaemic control to renal and cardiovascular protection Hiddo Lambers Heerspink Department of Clinical Pharmacy and Pharmacology University Medical Center
More informationStages of Chronic Kidney Disease (CKD)
Early Treatment is the Key Stages of Chronic Kidney Disease (CKD) Stage Description GFR (ml/min/1.73 m 2 ) >90 1 Kidney damage with normal or GFR 2 Mild decrease in GFR 60-89 3 Moderate decrease in GFR
More informationThe Diabetes Kidney Disease Connection Missouri Foundation for Health February 26, 2009
The Diabetes Kidney Disease Connection Missouri Foundation for Health February 26, 2009 Teresa Northcutt, RN BSN Primaris Program Manager, Prevention - CKD MO-09-01-CKD This material was prepared by Primaris,
More informationObjectives. Kidney Complications With Diabetes. Case 10/21/2015
Objectives Kidney Complications With Diabetes Brian Boerner, MD Diabetes, Endocrinology, and Metabolism University of Nebraska Medical Center Review screening for, and management of, albuminuria Review
More informationALLHAT RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 4 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR)
1 RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 4 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR) 6 / 5 / 1006-1 2 Introduction Hypertension is the second most common cause of end-stage
More informationQUICK REFERENCE FOR HEALTHCARE PROVIDERS
KEY MESSAGES 1 SCREENING CRITERIA Screen: Patients with DM and/or hypertension at least yearly. Consider screening patients with: Age >65 years old Family history of stage 5 CKD or hereditary kidney disease
More informationChronic Kidney Disease
Chronic Kidney Disease Chronic Kidney Disease (CKD) Educational Objectives Outline Demographics Propose Strategies to slow progression and improve outcomes Plan for treatment of CKD Chronic Kidney Disease
More informationDiabetic Nephropathy
Diabetic Nephropathy Objectives: Know what Diabetic Nephropathy means. Know how common is Diabetic nephropathy in Saudi Arabia and to appreciate how bad are this complications. Know the risk factors of
More informationManagement of Hypertension. M Misra MD MRCP (UK) Division of Nephrology University of Missouri School of Medicine
Management of Hypertension M Misra MD MRCP (UK) Division of Nephrology University of Missouri School of Medicine Disturbing Trends in Hypertension HTN awareness, treatment and control rates are decreasing
More informationGuest Speaker Evaluations Viewer Call-In Thanks to our Sponsors: Phone: Fax: Public Health Live T 2 B 2
Public Health Live T 2 B 2 Chronic Kidney Disease in Diabetes: Early Identification and Intervention Guest Speaker Joseph Vassalotti, MD, FASN Chief Medical Officer National Kidney Foundation Thanks to
More informationStandards of Medical Care in Diabetes 2018
Standards of Medical Care in Diabetes 2018 Eric L. Johnson, M.D. Associate Professor University of North Dakota School of Medicine and Health Sciences Assistant Medical Director Altru Diabetes Center Grand
More informationManaging patients with renal disease
Managing patients with renal disease Hiddo Lambers Heerspink, MD University Medical Centre Groningen, The Netherlands Asian Cardio Diabetes Forum April 23 24, 216 Kuala Lumpur, Malaysia Prevalent cases,
More informationDiabetic Nephropathy. Objectives:
There are, in truth, no specialties in medicine, since to know fully many of the most important diseases a man must be familiar with their manifestations in many organs. William Osler 1894. Objectives:
More informationDiabetes in Renal Patients. Contents. Understanding Diabetic Nephropathy
Diabetes in Renal Patients Contents Understanding Diabetic Nephropathy What effect does CKD have on a patient s diabetic control? Diabetic Drugs in CKD and Dialysis Patients Hyper and Hypoglycaemia in
More informationPrevention And Treatment of Diabetic Nephropathy. MOH Clinical Practice Guidelines 3/2006 Dr Stephen Chew Tec Huan
Prevention And Treatment of Diabetic Nephropathy MOH Clinical Practice Guidelines 3/2006 Dr Stephen Chew Tec Huan Prevention Tight glucose control reduces the development of diabetic nephropathy Progression
More informationHypertension and diabetic nephropathy
Hypertension and diabetic nephropathy Elisabeth R. Mathiesen Professor, Chief Physician, Dr sci Dep. Of Endocrinology Rigshospitalet, University of Copenhagen Denmark Hypertension Brain Eye Heart Kidney
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. ACE Inhibitor and Angiotensin II Antagonist Combination Treatment GUIDELINES
ACE Inhibitor and Angiotensin II Antagonist Combination Treatment Date written: September 2004 Final submission: September 2005 Author: Kathy Nicholls GUIDELINES No recommendations possible based on Level
More informationABCD and Renal Association Clinical Guidelines for Diabetic Nephropathy-CKD. Management of Dyslipidaemia and Hypertension in Adults Dr Peter Winocour
ABCD and Renal Association Clinical Guidelines for Diabetic Nephropathy-CKD. Management of Dyslipidaemia and Hypertension in Adults Dr Peter Winocour Dr Indranil Dasgupta Rationale No national practical
More informationUric acid and CKD. Sunil Badve Conjoint Associate Professor, UNSW Staff Specialist, St George
Uric acid and CKD Sunil Badve Conjoint Associate Professor, UNSW Staff Specialist, St George Hospital @Badves Case Mr J, 52 Male, referred in June 2015 DM type 2 (4 years), HTN, diabetic retinopathy, diabetic
More informationHYPERTENSION GUIDELINES WHERE ARE WE IN 2014
HYPERTENSION GUIDELINES WHERE ARE WE IN 2014 Donald J. DiPette MD FACP Special Assistant to the Provost for Health Affairs Distinguished Health Sciences Professor University of South Carolina University
More informationSLOWING PROGRESSION OF KIDNEY DISEASE. Mark Rosenberg MD University of Minnesota
SLOWING PROGRESSION OF KIDNEY DISEASE Mark Rosenberg MD University of Minnesota OUTLINE 1. Epidemiology of progression 2. Therapy to slow progression a. Blood Pressure control b. Renin-angiotensin-aldosterone
More informationCKDinform: A PCP s Guide to CKD Detection and Delaying Progression
CKDinform: A PCP s Guide to CKD Detection and Delaying Progression Learning Objectives Describe suitable screening tools, such as GFR and ACR, for proper utilization in clinical practice related to the
More information6/10/2014. Chronic Kidney Disease - General management and standard of care. Management of CKD according to stage (KDOQI 2002)
Chronic Kidney Disease - General management and standard of care Dr Nathalie Demoulin, Prof Michel Jadoul Cliniques universitaires Saint-Luc Université Catholique de Louvain What should and can be done
More informationTREAT THE KIDNEY TO SAVE THE HEART. Leanna Tyshler, MD Chronic Kidney Disease Medical Advisor Northwest Kidney Centers February 2 nd, 2009
TREAT THE KIDNEY TO SAVE THE HEART Leanna Tyshler, MD Chronic Kidney Disease Medical Advisor Northwest Kidney Centers February 2 nd, 2009 1 ESRD Prevalent Rates in 1996 per million population December
More information1. Albuminuria an early sign of glomerular damage and renal disease. albuminuria
1. Albuminuria an early sign of glomerular damage and renal disease albuminuria Cardio-renal continuum REGRESS Target organ damage Asymptomatic CKD New risk factors Atherosclerosis Target organ damage
More informationFaculty/Presenter Disclosure
CSI for CKD Unravelling the myths surrounding chronic kidney disease Practical Evidence for Informed Practice Oct 21 2016 Dr. Scott Klarenbach University of Alberta Slide 1: Option B (Presenter with NO
More informationAddressing Chronic Kidney Disease in People with Multiple Chronic Conditions
Addressing Chronic Kidney Disease in People with Multiple Chronic Conditions Andrew S Narva, MD Na/onal Kidney Disease Educa/on Program U.S. Department of Health and Human Services National Institute of
More informationDiabetic Kidney Disease in the Primary Care Clinic
Diabetic Kidney Disease in the Primary Care Clinic Jess Wheeler, DO Nephrology 2015 Outline: 1. CKD/DKD is a growing problem 2. Diagnosis of Chronic Kidney Disease (CKD) 3. Diagnosis of Diabetic Kidney
More informationNew Hypertension Guideline Recommendations for Adults July 7, :45-9:30am
Advances in Cardiovascular Disease 30 th Annual Convention and Reunion UERM-CMAA, Inc. Annual Convention and Scientific Meeting July 5-8, 2018 New Hypertension Guideline Recommendations for Adults July
More informationManagement of early chronic kidney disease
Management of early chronic kidney disease GREENLANE SUMMER GP SYMPOSIUM 2018 Jonathan Hsiao Renal and General Physician Introduction A growing public health problem in NZ and throughout the world. Unknown
More informationHot Topics in Diabetic Kidney Disease a primary care perspective
Hot Topics in Diabetic Kidney Disease a primary care perspective DR SARAH DAVIES GP PARTNER WITH SPECIAL INTEREST IN DIABETES, CARDIFF DUK CLINICAL CHAMPION NB MEDICAL HOT TOPICS PRESENTER AND DIABETES
More informationObjectives. Pre-dialysis CKD: The Problem. Pre-dialysis CKD: The Problem. Objectives
The Role of the Primary Physician and the Nephrologist in the Management of Chronic Kidney Disease () By Brian Young, M.D. Assistant Clinical Professor of Medicine David Geffen School of Medicine at UCLA
More informationPredicting and changing the future for people with CKD
Predicting and changing the future for people with CKD I. David Weiner, M.D. Co-holder, C. Craig and Audrae Tisher Chair in Nephrology Professor of Medicine and Physiology and Functional Genomics University
More informationDisclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease
Disclosures Diabetes and Cardiovascular Risk Management Tony Hampton, MD, MBA Medical Director Advocate Aurora Operating System Advocate Aurora Healthcare Downers Grove, IL No conflicts or disclosures
More informationChronic Kidney Disease Management for Primary Care Physicians. Dr. Allen Liu Consultant Nephrologist KTPH 21 November 2015
Chronic Kidney Disease Management for Primary Care Physicians Dr. Allen Liu Consultant Nephrologist KTPH 21 November 2015 Singapore Renal Registry 2012 Incidence of Patients on Dialysis by Mode of Dialysis
More informationInterventions to reduce progression of CKD what is the evidence? John Feehally
Interventions to reduce progression of CKD what is the evidence? John Feehally Interventions to reduce progression of CKD what is the evidence? CHALLENGES Understanding what we know. NOT.what we think
More informationDISCLOSURES OUTLINE OUTLINE 9/29/2014 ANTI-HYPERTENSIVE MANAGEMENT OF CHRONIC KIDNEY DISEASE
ANTI-HYPERTENSIVE MANAGEMENT OF CHRONIC KIDNEY DISEASE DISCLOSURES Editor-in-Chief- Nephrology- UpToDate- (Wolters Klewer) Richard J. Glassock, MD, MACP Geffen School of Medicine at UCLA 1 st Annual Internal
More informationAmerican Diabetes Association 2018 Guidelines Important Notable Points
American Diabetes Association 2018 Guidelines Important Notable Points The Standards of Medical Care in Diabetes-2018 by ADA include the most current evidencebased recommendations for diagnosing and treating
More informationWhat s In the New Hypertension Guidelines?
American College of Physicians Ohio/Air Force Chapters 2018 Scientific Meeting Columbus, OH October 5, 2018 What s In the New Hypertension Guidelines? Max C. Reif, MD, FACP Objectives: At the end of the
More informationMetabolic Syndrome and Chronic Kidney Disease
Metabolic Syndrome and Chronic Kidney Disease Definition of Metabolic Syndrome National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III Abdominal obesity, defined as a waist circumference
More informationChronic Kidney Disease for the Primary Care Physician in What do the Kidneys do? CKD in the US
1:25-2:25pm Managing Chronic Kidney Disease in 2019 SPEAKERS Adriana Dejman, MD Chronic Kidney Disease for the Primary Care Physician in 2019 Adriana Dejman, MD Assistant Professor of Clinical Medicine
More informationSwindon Diabetes Guidelines: Management of Chronic Kidney Disease Associated with Diabetes Mellitus
Swindon Diabetes Guidelines: Management of Chronic Kidney Disease Associated with Diabetes Mellitus 1 Contents Executive Summary... 3 How to Screen for Diabetic Nephropathy... 4 What to Measure... 4 Frequency
More informationDiabetic Kidney Disease Tripti Singh MD Department of Nephrology University of Wisconsin
Diabetic Kidney Disease Tripti Singh MD Department of Nephrology University of Wisconsin Disclosures I have no financial relationship with the manufacturers of any commercial product discussed during this
More informationReframe the Paradigm of Hypertension treatment Focus on Diabetes
Reframe the Paradigm of Hypertension treatment Focus on Diabetes Paola Atallah, MD Lecturer of Clinical Medicine SGUMC EDL monthly meeting October 25,2016 Overview Physiopathology of hypertension Classification
More informationKidney Disease, Hypertension and Cardiovascular Risk
1 Kidney Disease, Hypertension and Cardiovascular Risk George Bakris, MD, FAHA, FASN Professor of Medicine Director, Hypertensive Diseases Unit The University of Chicago-Pritzker School of Medicine Chicago,
More informationCreatinine & egfr A Clinical Perspective. Suheir Assady MD, PhD Dept. of Nephrology & Hypertension RHCC
Creatinine & egfr A Clinical Perspective Suheir Assady MD, PhD Dept. of Nephrology & Hypertension RHCC CLINICAL CONDITIONS WHERE ASSESSMENT OF GFR IS IMPORTANT Stevens et al. J Am Soc Nephrol 20: 2305
More informationDiabetes and kidney disease.
Diabetes and kidney disease. What are the implications? Can it be prevented? Nice 18 june 2010 Lars G Weiss. M.D. Ph.D. Department of Neprology Central Hospital Karlstad Sweden Diabetic nephropathy vs
More informationUniversity of Groningen. Evaluation of renal end points in nephrology trials Weldegiorgis, Misghina Tekeste
University of Groningen Evaluation of renal end points in nephrology trials Weldegiorgis, Misghina Tekeste IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish
More informationQuality ID #119 (NQF 0062): Diabetes: Medical Attention for Nephropathy National Quality Strategy Domain: Effective Clinical Care
Quality ID #119 (NQF 0062): Diabetes: Medical Attention for Nephropathy National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS F INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Process
More informationDiabetic Nephropathy 2009
Diabetic Nephropathy 2009 Michael T McDermott MD Director, Endocrinology and Diabetes Practice University of Colorado Hospital Michael.mcdermott@ucdenver.edu Diabetic Nephropathy Clinical Stages Hyperfunction
More informationMorbidity & Mortality from Chronic Kidney Disease
Morbidity & Mortality from Chronic Kidney Disease Dr. Lam Man-Fai ( 林萬斐醫生 ) Honorary Clinical Assistant Professor MBBS, MRCP, FHKCP, FHKAM, PDipID (HK), FRCP (Edin, Glasg) Hong Kong Renal Registry Report
More informationOutline. Outline CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW. Question 1: Which of these patients has CKD?
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationManagement of Early Kidney Disease: What to do Before Referring to the Nephrologist
Management of Early Kidney Disease: What to do Before Referring to the Nephrologist Andrew S. Narva, MD, NIDDK Saturday, February 18, 2017 8:45 a.m. 9:30 a.m. Although evidence-based guidelines for managing
More informationRENAAL, IRMA-2 and IDNT. Three featured trials linking a disease spectrum IDNT RENAAL. Death IRMA 2
Treatment of Diabetic Nephropathy and Proteinuria Background End stage renal disease is a major cause of death and disability among diabetics BP reduction is important to slow the progression of diabetic
More informationChapter 1: CKD in the General Population
Chapter 1: CKD in the General Population Overall prevalence of CKD (Stages 1-5) in the U.S. adult general population was 14.8% in 2011-2014. CKD Stage 3 is the most prevalent (NHANES: Figure 1.2 and Table
More informationVariability in drug response: towards more personalized diabetes care Petrykiv, Sergei
University of Groningen Variability in drug response: towards more personalized diabetes care Petrykiv, Sergei IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you
More informationHYPERTENSION IN CKD. LEENA ONGAJYOOTH, M.D., Dr.med RENAL UNIT SIRIRAJ HOSPITAL
HYPERTENSION IN CKD LEENA ONGAJYOOTH, M.D., Dr.med RENAL UNIT SIRIRAJ HOSPITAL Stages in Progression of Chronic Kidney Disease and Therapeutic Strategies Complications Normal Increased risk Damage GFR
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Protein Restriction to prevent the progression of diabetic nephropathy GUIDELINES
Protein Restriction to prevent the progression of diabetic nephropathy Date written: September 2004 Final submission: September 2005 Author: Kathy Nicholls GUIDELINES a. A small volume of evidence suggests
More informationVA/DoD Clinical Practice Guideline for the Management of Chronic Kidney Disease in Primary Care (2008) PROVIDER REFERENCE CARDS Chronic Kidney Disease
VA/DoD Clinical Practice Guideline for the Management of Chronic Kidney Disease in Primary Care (2008) PROVIDER REFERECE CARDS Chronic Kidney Disease CKD VA/DoD Clinical Practice Guideline for the Management
More informationCKD and risk management : NICE guideline
CKD and risk management : NICE guideline 2008-2014 Shahed Ahmed Consultant Nephrologist shahed.ahmed@rlbuht.nhs.uk Key points : Changing parameters of CKD and NICE guidance CKD and age related change of
More information2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process
Quality ID #119 (NQF 0062): Diabetes: Medical Attention for Nephropathy National Quality Strategy Domain: Effective Clinical Care Meaningful Measure Area: Management of Chronic Conditions 2019 COLLECTION
More informationDisclosures. Outline. Outline 5/23/17 CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationOffice Management of Reduced GFR Practical advice for the management of CKD
Office Management of Reduced GFR Practical advice for the management of CKD CKD Online Education CME for Primary Care April 27, 2016 Monica Beaulieu, MD FRCPC MHA CHAIR PROVINCIAL KIDNEY CARE COMMITTEE
More informationCHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationDisclosures. Outline. Outline 7/27/2017 CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationOutline. Outline CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW 7/23/2013. Question 1: Which of these patients has CKD?
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationOutline. Outline 10/14/2014 CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW. Question 1: Which of these patients has CKD?
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationIrish Practice Nurses Association Annual Conference Tullamore Court Hotel OCTOBER 6 th 2012
Irish Practice Nurses Association Annual Conference Tullamore Court Hotel OCTOBER 6 th 2012 Susan McKenna Renal Clinical Nurse Specialist Cavan General Hospital Renal patient population ACUTE RENAL FAILURE
More informationCHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH SCIENTIFIC DIRECTOR KIDNEY HEALTH RESEARCH COLLABORATIVE - UCSF CHIEF - GENERAL INTERNAL MEDICINE, SAN FRANCISCO
More informationJNC Evidence-Based Guidelines for the Management of High Blood Pressure in Adults
JNC 8 2014 Evidence-Based Guidelines for the Management of High Blood Pressure in Adults Table of Contents Why Do We Treat Hypertension? Blood Pressure Treatment Goals Initial Therapy Strength of Recommendation
More informationChronic kidney disease-what can you do and when to refer?
Chronic kidney disease-what can you do and when to refer? Dr Goh Heong Keong www.passpaces.com/kidney.htm Outline of Lecture Introduction Epidemiology of CKD in Malaysia/ World Complications of CKD What
More informationKidney disease in people with diabetes. Ian Gallen
Kidney disease in people with diabetes Ian Gallen Why is it important Major cause of early death in DM Major cause of amputation RRT is arduous for the patient and expensive Nephropathy is largely avoidable
More informationThe CARI Guidelines Caring for Australians with Renal Impairment. Specific effects of calcium channel blockers in diabetic nephropathy GUIDELINES
Specific effects of calcium channel blockers in diabetic nephropathy Date written: September 2004 Final submission: September 2005 Author: Kathy Nicholls GUIDELINES a. Non-dihydropyridine calcium channel
More informationVA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005
VA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005 1 Any adult in the health care system 2 Obtain blood pressure (BP) (Reliable,
More informationDiabetic Kidney Disease: Update. GKA Master Class. Istanbul 2011
Diabetic Kidney Disease: Update GKA Master Class Istanbul 2011 DKD: Challenging dogmas Old Dogmas Type 1 and Type 2 DN have the same natural history Microalbuminuria is an early stage of DN Tight Glycemia
More informationBASELINE CHARACTERISTICS OF THE STUDY POPULATION
Study Summary DAILY ORAL SODIUM BICARBONATE PRESERVES GLOMERULAR FILTRATION RATE BY SLOWING ITS DECLINE IN EARLY HYPERTENSIVE NEPHROPATHY This was a 5-year, single-center, prospective, randomized, placebo-controlled,
More informationAggressive blood pressure reduction and renin angiotensin system blockade in chronic kidney disease: time for re-evaluation?
http://www.kidney-international.org & 2013 International Society of Nephrology Aggressive blood pressure reduction and renin angiotensin system blockade in chronic kidney disease: time for re-evaluation?
More informationWhat should you do next? Presenter Disclosure Information. Learning Objectives. Case: George
2:45 3:45pm Optimizing the Management of Patients with Chronic Kidney Disease SPEAKER Jay B. Wish, MD, FACP Presenter Disclosure Information The following relationships exist related to this presentation:
More informationE.Ritz Heidelberg (Germany)
Predictive capacity of renal function in cardiovascular disease E.Ritz Heidelberg (Germany) If a cure is not achieved, the kidneys will pass on the disease to the heart Huang Ti Nei Ching Su Wen The Yellow
More informationNew Treatment Options for Diabetic Nephropathy patients. Prof. M. Burnier, Service of Nephrology and Hypertension CHUV, Lausanne, Switzerland
New Treatment Options for Diabetic Nephropathy patients Prof. M. Burnier, Service of Nephrology and Hypertension CHUV, Lausanne, Switzerland Diabetes and nephropathy Diabetic nephropathy is the most common
More informationUpdate on HIV-Related Kidney Diseases. Agenda
Update on HIV-Related Kidney Diseases ANDY CHOI THE MEDICAL MANAGEMENT OF HIV/AIDS DECEMBER 15, 2006 Agenda 1. EPIDEMIOLOGY: A) END STAGE RENAL DISEASE (ESRD) B) CHRONIC KIDNEY DISEASE (CKD) 2. HIV-ASSOCIATED
More informationDifficult to Treat Hypertension
Difficult to Treat Hypertension According to Goldilocks JNC 8 Blood Pressure Goals (2014) BP Goal 60 years old and greater*- systolic < 150 and diastolic < 90. (Grade A)** BP Goal 18-59 years old* diastolic
More informationHypertension in 2015: SPRINT-ing ahead of JNC-8. MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic
Hypertension in 2015: SPRINT-ing ahead of JNC-8 MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic Conflits of interest? None Disclaimer The opinions contained herein are not to be considered
More informationSession 9: Optimizing the Management of Patients with Chronic Kidney Disease Learning Objectives
Session 9: Optimizing the Management of Patients with Chronic Kidney Disease Learning Objectives 1. Understand the impact of chronic kidney disease (CKD) as a common condition of the adult US population.
More informationApplying clinical guidelines treating and managing CKD
Applying clinical guidelines treating and managing CKD Develop patient treatment plan according to level of severity. Source: Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012
More informationDiabetes and Kidney Disease. Kris Bentley Renal Nurse practitioner 2018
Diabetes and Kidney Disease Kris Bentley Renal Nurse practitioner 2018 Aims Develop an understanding of Chronic Kidney Disease Understand how diabetes impacts on your kidneys Be able to recognise the risk
More informationTread Carefully Because you Tread on my Nephrons. Prescribing Hints in Renal Disease
Tread Carefully Because you Tread on my Nephrons Prescribing Hints in Renal Disease David WP Lappin,, MB PhD FRCPI Clinical Lecturer in Medicine and Consultant Nephrologist and General Physician, Merlin
More informationSection Questions Answers
Section Questions Answers Guide to CKD Screening and Evaluation -Alec Otteman, MD Delaying Progression - Paul Drawz, MD, MHS, MS 1. Modifiable risk factors for CKD include: a. Diabetes b. Hypertension
More informationLessons learned from AASK (African-American Study of Kidney Disease and Hypertension)
Lessons learned from AASK (African-American Study of Kidney Disease and Hypertension) Janice P. Lea, MD, MSc, FASN Professor of Medicine Chief Medical Director of Emory Dialysis ASH Clinical Specialist
More informationDiabetic Kidney Disease Tripti Singh MD Department of Nephrology University of Wisconsin
Diabetic Kidney Disease Tripti Singh MD Department of Nephrology University of Wisconsin Disclosures I have no financial relationship with the manufacturers of any commercial product discussed during this
More informationSPRINT: Consequences for CKD patients
SPRINT: Consequences for CKD patients 29 e Workshop Nierziekten Papendal 2018 December 12, 2018 MICHAEL ROCCO, MD, MSCE VARDAMAN M. BUCKALEW JR. PROFESSOR OF MEDICINE PROFESSOR OF PUBLIC HEALTH SCIENCES
More informationSystolic Blood Pressure Intervention Trial (SPRINT)
09:30-09:50 2016.4.15 Systolic Blood Pressure Intervention Trial (SPRINT) IN A NEPHROLOGIST S VIEW Sejoong Kim Seoul National University Bundang Hospital Current guidelines for BP control Lowering BP
More informationUpdates in Chronic Kidney Disease Management. Delphine S. Tuot, MDCM, MAS Associate Professor of Medicine UCSF-ZSFG
Updates in Chronic Kidney Disease Management Delphine S. Tuot, MDCM, MAS Associate Professor of Medicine UCSF-ZSFG No disclosures Research Funding: NIH, Blue Shield of California Foundation Objectives
More informationManagement of New-Onset Proteinuria in the Ambulatory Care Setting. Akinlolu Ojo, MD, PhD, MBA
Management of New-Onset Proteinuria in the Ambulatory Care Setting Akinlolu Ojo, MD, PhD, MBA Urine dipstick results Negative Trace between 15 and 30 mg/dl 1+ between 30 and 100 mg/dl 2+ between 100 and
More informationCardiovascular Pharmacotherapy in Special Population: Cardio-Nephrology
49 th Annual Scientific Meeting The Heart Association of Thailand under the Royal Patronage of H.M. the King Cardiology on the move 24-25 March 2017 @Sheraton, HuaHin Cardiovascular Pharmacotherapy in
More informationTreating Hypertension in 2018: What Makes the Most Sense Today?
Treating Hypertension in 2018: What Makes the Most Sense Today? Daniel Blanchard, MD Professor of Medicine UC San Diego Cardiovascular Center La Jolla, California 1 2 Speaker Disclosures Consultant and/or
More information